RESISTANT HYPERTENSION: WHEN DRUG THERAPY IS THE CULPRIT
Ilaria Ambrosino,Giulia Rivasi,Marco Capacci,Ludovica Ceolin,Lorenza Rossi,Francesca Bisignano,Alessandra Liccardo,Giuseppe D’Ambrosio,Greta Ceccarelli,Andrea Ungar
DOI: https://doi.org/10.1097/01.hjh.0001022228.56019.71
IF: 4.9
2024-05-01
Journal of Hypertension
Abstract:Objective: Resistant Hypertension is not uncommon in clinical practice. The causal role of medical therapy is often underestimated. Design and method: We describe a case of (pseudo)Resistant Hypertension where medications contributed to (pseudo)resistance. Results: An 83-year-old male patient was referred to our Hypertension Clinic in July 2020 for poor blood pressure (BP) control despite polytherapy (Valsartan 320 mg/die, Nebivolol 5 mg/die, Doxazosin 4 mg/die, Clonidine patch 5 mg/die, Lercanidipine 20 mg). Medical history included recent stroke (June 2020), hypercholesterolemia, hyperuricemia, hypothyroidism, and previous right nephrectomy for renal carcinoma (2010), on treatment with the Tyr-kinase receptor inhibitor Sunitinib (2 weeks/month) at the time of assessment. He reported a recent Emergency Department visit for high BP (210/105 mmHg), with no target organ damage. Mean home BP was 160/70 mmHg. Lercanidipine was stopped due to poor tolerability (ankle swelling) and Canrenone 50 mg/die was introduced. A month later, 24-hours Ambulatory Blood Pressure Monitoring (ABPM) showed persistence of inadequate BP control (mean 24h BP 151/68 mmHg, mean daytime BP 152/70 mmHg). As Doxazosin (α1-receptors antagonist) and Clonidine (α2-receptors agonist) both act on alfa-adrenergic receptors, but in opposite way, Doxazosin was progressively reduced and then withdrawn, with subsequent improvement of BP control. However, high BP variability persisted. Home BP diary showed higher values while on Sunitinib treatment and lower BP during washout periods (Figure 1). Indeed, Sunitinib is associated with a 15-25% incidence of hypertension. Moreover, some studies demonstrate a correlation between Sunitinib treatment and marked BP increases. Therefore, patient's treatment was modulated increasing BP medications during Sunitinib cycles and reducing antihypertensive treatment intensity during washout periods. Conclusions: The present case report highlights the clinical relevance of iatrogenic resistant hypertension, that is often overlooked in clinical practice, particularly if related to non-routine medications, e.g. antiangiogenic agents. Moreover, this case report draws attention to pseudoresistant hypertension caused by inappropriate antihypertensive associations such as Doxazosin and Clonidine. Indeed, these drugs are highly specific for α1 and α2-receptors, respectively, but they can also bind other receptor subclasses, thus potentially interfering each other due to competitive binding.
peripheral vascular disease